X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (647) 647
Publication (131) 131
Book Review (68) 68
Conference Proceeding (59) 59
Book Chapter (13) 13
Patent (9) 9
Reference (8) 8
Book / eBook (3) 3
Newspaper Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (389) 389
humans (383) 383
oncology (370) 370
female (343) 343
breast neoplasms - drug therapy (227) 227
breast cancer (199) 199
middle aged (192) 192
aged (178) 178
adult (168) 168
breast neoplasms - pathology (167) 167
chemotherapy (126) 126
cancer (97) 97
antineoplastic combined chemotherapy protocols - therapeutic use (92) 92
treatment outcome (92) 92
article (91) 91
therapy (75) 75
aged, 80 and over (69) 69
chemotherapy, adjuvant (69) 69
prognosis (66) 66
neoplasm staging (64) 64
trastuzumab (64) 64
women (62) 62
survival (60) 60
abridged index medicus (58) 58
antineoplastic combined chemotherapy protocols - adverse effects (58) 58
breast neoplasms - mortality (58) 58
breast neoplasms - surgery (54) 54
disease-free survival (53) 53
breast neoplasms - metabolism (52) 52
risk factors (52) 52
adjuvant chemotherapy (51) 51
paclitaxel (51) 51
care and treatment (50) 50
paclitaxel - administration & dosage (50) 50
breast neoplasms - therapy (49) 49
receptor, erbb-2 - metabolism (47) 47
medicine & public health (45) 45
research (44) 44
breast neoplasms - genetics (41) 41
drug administration schedule (41) 41
neoplasm metastasis (41) 41
randomized-trial (41) 41
health aspects (40) 40
retrospective studies (39) 39
trial (39) 39
antineoplastic agents - therapeutic use (38) 38
cyclophosphamide - administration & dosage (37) 37
follow-up studies (37) 37
risk (37) 37
dose-response relationship, drug (36) 36
antineoplastic combined chemotherapy protocols - administration & dosage (34) 34
postmenopausal women (34) 34
antibodies, monoclonal, humanized (33) 33
mastectomy (32) 32
doxorubicin (31) 31
drug therapy (31) 31
paclitaxel - adverse effects (31) 31
time factors (31) 31
lymphatic metastasis (30) 30
cyclophosphamide (29) 29
hematology, oncology and palliative medicine (29) 29
survival analysis (29) 29
tamoxifen (29) 29
antineoplastic agents - adverse effects (28) 28
carcinoma (27) 27
doxorubicin - administration & dosage (27) 27
male (27) 27
surgery (27) 27
age factors (25) 25
clinical trials (25) 25
metastasis (25) 25
randomized controlled trials as topic (25) 25
united states (25) 25
breast-cancer (24) 24
kaplan-meier estimate (24) 24
obesity (24) 24
original reports (24) 24
quality of life (24) 24
receptor, erbb-2 - genetics (24) 24
risk assessment (24) 24
combined modality therapy (23) 23
inflammation (23) 23
survival rate (23) 23
tumors (23) 23
antibodies, monoclonal - administration & dosage (22) 22
antineoplastic agents - administration & dosage (22) 22
bevacizumab (22) 22
her2 (22) 22
skin and connective tissue diseases (22) 22
adjuvant treatment (21) 21
animals (21) 21
efficacy (21) 21
expression (21) 21
follow-up (21) 21
young adult (21) 21
gene-expression (20) 20
immunohistochemistry (20) 20
paclitaxel - therapeutic use (20) 20
quality-of-life (20) 20
recurrence (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 21, pp. 2079 - 2080
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 55 - 65
Summary Background The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with... 
Hematology, Oncology and Palliative Medicine | INTERNATIONAL EXPERT CONSENSUS | SURVIVAL | PRIMARY THERAPY | ONCOLOGY | RECOMMENDATIONS | GENE-EXPRESSION | RISK | HIGHLIGHTS | DEATH | SIGNATURE | TUMOR-MARKER | Doxorubicin - therapeutic use | Predictive Value of Tests | Recurrence | United States - epidemiology | Breast Neoplasms - secondary | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Gene Expression Profiling | Receptors, Estrogen - analysis | Genetic Testing - methods | Cyclophosphamide - therapeutic use | Patient Selection | Fluorouracil - therapeutic use | Breast Neoplasms - chemistry | Clinical Trials, Phase III as Topic | Time Factors | Postmenopause | Adult | Female | Retrospective Studies | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Lymphatic Metastasis | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Disease-Free Survival | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Chemotherapy | Cyclophosphamide | Clinical trials | genomics | Breast cancer | Tamoxifen | Doxorubicin | Survival | Nodes | Post-menopause | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2016, Volume 375, Issue 8, pp. 790 - 791
Journal Article
Cancer, ISSN 0008-543X, 07/2019
Journal Article
Nature, ISSN 0028-0836, 05/2014, Volume 509, Issue 7502, pp. 491 - 492
Journal Article
Nature Genetics, ISSN 1061-4036, 12/2013, Volume 45, Issue 12, pp. 1439 - 1445
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5218 - 5224
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 3, pp. 209 - 219
Journal Article
2004, Breast disease, ISBN 9781586035006, vi, 64
Book
by Tefferi, Ayalew, MD and Kantarjian, Hagop, MD and Rajkumar, S. Vincent, MD and Baker, Lawrence H., DO and Abkowitz, Jan L., MD and Adamson, John W., MD and Advani, Ranjana Hira, MD and Allison, James, MD and Antman, Karen H., MD and Bast, Robert C., MD and Bennett, John M., MD and Benz, Edward J., MD and Berliner, Nancy, MD and Bertino, Joseph, MD and Bhatia, Ravi, MD and Bhatia, Smita, MD and Bhojwani, Deepa, MD and Blanke, Charles D., MD and Bloomfield, Clara D., MD and Bosserman, Linda, MD and Broxmeyer, Hal E., PhD and Byrd, John C., MD and Cabanillas, Fernando, MD and Canellos, George Peter, MD and Chabner, Bruce A., MD and Chanan-Khan, Asher, MD and Cheson, Bruce, MD and Clarkson, Bayard, MD and Cohn, Susan L., MD and Colon-Otero, Gerardo, MD and Cortes, Jorge, MD and Coutre, Steven, MD and Cristofanilli, Massimo, MD and Curran, Walter J., MD and Daley, George Q., MD, PhD and DeAngelo, Daniel J., MD, PhD and Deeg, H. Joachim, MD and Einhorn, Lawrence H., MD and Erba, Harry P., MD, PhD and Esteva, Francisco J., MD, PhD and Estey, Elihu, MD and Fidler, Isaiah J., DVM, PhD and Foran, James, MD and Forman, Stephen, MD and Freireich, Emil, MD and Fuchs, Charles, MD, MPH and George, James N., MD and Gertz, Morie A., MD and Giralt, Sergio, MD and Golomb, Harvey, MD and Greenberg, Peter, MD and Gutterman, Jordan, MD and Handin, Robert I., MD and Hellman, Samuel, MD and Hoff, Paulo Marcelo, MD and Hoffman, Ronald, MD and Hong, Waun Ki, MD and Horowitz, Mary, MD, MS and Hortobagyi, Gabriel N., MD and Hudis, Clifford, MD and Issa, Jean Pierre, MD and Johnson, Bruce Evan, MD and Kantoff, Philip W., MD and Kaushansky, Kenneth, MD and Khayat, David, MD, PhD and Khuri, Fadlo R., MD and Kipps, Thomas J., MD, PhD and Kripke, Margaret, PhD and Kyle, Robert A., MD and Larson, Richard A., MD and Lawrence, Theodore S., MD, PhD and Levine, Ross, MD and Link, Michael P., MD and Lippman, Scott M., MD and Lonial, Sagar, MD and Lyman, Gary H., MD, MPH and Markman, Maurie, MD and Mendelsohn, John, MD and Meropol, Neal J., MD and Messinger, Yoav, MD and Mulvey, Therese M., MD and O’Brien, Susan, MD and Perez-Soler, Roman, MD and Pollock, Raphael, MD, PhD and Prchal, Josef, MD and Press, Oliver, MD, PhD and Radich, Jerald, MD and Rai, Kanti, MD and Rosenberg, Saul A., MD and Rowe, Jacob M., MD and Rugo, Hope, MD and Runowicz, Carolyn D., MD and Sandmaier, Brenda M., MD and Saven, Alan, MD and Schafer, Andrew I., MD and Schiffer, Charles, MD and Sekeres, Mikkael A., MD, MS and Silver, Richard T., MD and Siu, Lillian L., MD and Steensma, David P., MD and ...
Mayo Clinic Proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 8, pp. 996 - 1000
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 134 - 141
A multicenter single-group trial suggests that adjuvant therapy with paclitaxel plus trastuzumab lowers the risk of relapse in women with small HER2-positive... 
OVEREXPRESSION | WOMEN | MEDICINE, GENERAL & INTERNAL | ONCOGENE | EFFICACY | SAFETY | RISK | MONOCLONAL-ANTIBODY | CHEMOTHERAPY | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - therapy | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Mastectomy, Segmental | Aged, 80 and over | Adult | Female | Receptor, ErbB-2 - immunology | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Adenocarcinoma - chemistry | Antibodies, Monoclonal, Humanized - adverse effects | Neoplasm Recurrence, Local | Paclitaxel - adverse effects | Survival Rate | Radiotherapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma - mortality | Breast cancer | Dosage and administration | Drug therapy | Risk factors | Paclitaxel | Invasiveness | Clinical trials | Congestive heart failure | Neuropathy | Cancer therapies | Survival | Patients | ErbB-2 protein | Metastases | Chemotherapy | Epidermal growth factor | Ventricle | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Breast, The, ISSN 0960-9776, 2011, Volume 20, pp. S22 - S22
Journal Article
Journal Article
Journal Article